ライフサイエンスコーパス: dosing regimen

1 f the antiangiogenic agent sunitinib (a 2-wk dosing regimen).

2 half-life, necessitating a three times daily dosing regimen.

3 IGlar OD do not support a three-times-weekly dosing regimen.

4 had a good, similar safety profile with each dosing regimen.

5 h lower costs compared with a fixed, monthly dosing regimen.

6 d FcgammaRI/FcgammaRIII, following a chronic dosing regimen.

7 at in vehicle-treated controls over the 2-wk dosing regimen.

8 titration, was the most effective and safest dosing regimen.

9 aimed to select the most favourable dose and dosing regimen.

10 farin and to ascertain an optimal tecarfarin dosing regimen.

11 response and three partial responses in each dosing regimen.

12 a an ex vivo binding assay following an oral dosing regimen.

13 noglobulin G antibodies, supporting a 3-week dosing regimen.

14 und (SC-51322) to AGN 197727 in the systemic dosing regimen.

15 remained more symptomatic regardless of the dosing regimen.

16 tment keeping and > or =80% adherence to the dosing regimen.

17 set of GH deficiency, age of the patient and dosing regimen.

18 antages of oral bioavailability and flexible dosing regimen.

19 ression could be controlled by the rapamycin dosing regimen.

20 2-CdA were linear and predictable with this dosing regimen.

21 es iron absorption and might be a preferable dosing regimen.

22 rit additional evaluation of the once-weekly dosing regimen.

23 ry function for 4-6 months during a 12 month dosing regimen.

24 ntly proposed optimal allometric miltefosine dosing regimen.

25 11.3 to 37.6), supporting a once-daily oral dosing regimen.

26 488 (0-50 mug) according to a within-subject dosing regimen.

27 time ever) by the FDA, based on a new, safer dosing regimen.

28 ationale for clinical testing of alternative dosing regimens.

29 ect and toxicity with standard and alternate dosing regimens.

30 eater visual improvement and more convenient dosing regimens.

31 acokinetic effects between the two elinogrel dosing regimens.

32 treated with IL-21 by using three different dosing regimens.

33 ial therapeutic benefit using well-tolerable dosing regimens.

34 in combination with each of the chemotherapy dosing regimens.

35 2-dose regimen and was inferior to all other dosing regimens.

36 ctiveness, and feasibility of individualized dosing regimens.

37 A receptor agonist binodenoson, using 1 of 4 dosing regimens.

38 at can then be used to design individualized dosing regimens.

39 and pdFIX were similar with all comparative dosing regimens.

40 suffer from rapid clearance requiring 3-day dosing regimens.

41 , 69.4] twice daily; p=0.33) between the two dosing regimens.

42 to ranibizumab or bevacizumab and to 1 of 3 dosing regimens.

43 Typical side effects also occurred at low dosing regimens.

44 vitro immunologic activity of the different dosing regimens.

45 to ranibizumab or bevacizumab and to 1 of 3 dosing regimens.

46 s of ranibizumab or bevacizumab under 1 of 3 dosing regimens.

47 patients receiving once-daily vs twice-daily dosing regimens.

48 ly effective in vivo activity, even with low dosing regimens.

49 es and lack of patient adherence to frequent dosing regimens.

50 nt outcomes, drug deployment strategies, and dosing regimens.

51 received placebo or one of three ALS-008176 dosing regimens: 1 loading dose of 750 mg followed by 9

52 oth erythropoietin groups were futile (first dosing regimen: 17/35 [48.6%; 95% CI, 31.4% to 66.0%], P

53 6%; 95% CI, 31.4% to 66.0%], P = .13; second dosing regimen: 17/57 [29.8%; 95% CI, 18.4% to 43.4%], P

54 randomly assigned to one of three paclitaxel dosing regimens-175 mg/m(2), 210 mg/m(2), or 250 mg/m(2)

55 emurafenib outside of trials with individual dosing regimens (240-1920 mg/d; median treatment duratio

56 ol (hydrocortisone, HCT) using two different dosing regimens (25 mg/day over 4 days, 100 mg single do

57 Palifermin administered at the indicated dosing regimen (40 microg/kg for 3 consecutive days) bef

58 ntration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d).

59 After a daily dosing regimen, a shift to excitatory-inhibitory balance

60 Current dosing regimens achieved target concentrations for merop

61 At 1 and 2 weeks after the 4 d dosing regimen, acute FEN (1.5 or 3.0 mg/kg, i.v.) produ

62 studies were performed with two lisofylline dosing regimens added to fluid resuscitation in a shock

63 ed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in ac

64 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at basel

65 data from clinical trials evaluating various dosing regimens against the patient's disease, lifestyle

66 sign of the next trial to determine a repeat dosing regimen aimed at establishing a steady-state Treg

67 and physician compliance by simplifying the dosing regimen and clarifying endocarditis risk.

68 ant further studies to establish the optimal dosing regimen and efficacy.

69 ed open-label pexacerfont following the same dosing regimen and had cerebrospinal fluid sampled to es

70 ment of pediatric uveitis, including optimal dosing regimen and long-term efficacy.

71 rug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady st

72 ere scored (0-5) by a radiologist blinded to dosing regimen and time interval.

73 Exploration of alternative dosing regimens and combinatorial therapies with vaccine

74 Dosing regimens and consequent drug exposures that ampli

75 ed 5,000 Monte Carlo simulations for various dosing regimens and minimal inhibitory concentration and

76 elopment of biomarkers to define appropriate dosing regimens and predict which patients may benefit f

77 dual patient data on SAEs, assigned drug and dosing regimen, and baseline prognostic factors were req

78 nd strong translational evidence, an optimal dosing regimen, and better tolerability.

79 the potential of metabolic imaging for dose, dosing regimen, and compound selection in early-phase tr

80 Drug, dosing regimen, and genotype had no statistically signif

81 paradigm in terms of the treatment goal and dosing regimen, and provides a method to address the unm

82 or with pharmacokinetic properties, flexible dosing regimen, and suite of target engagement biomarker

83 ly limited by small sample sizes, inadequate dosing regimens, and high baseline vitamin D status amon

84 oxicology studies, selection of first in man dosing regimens, and PK/PD model development.

85 lied on an outpatient basis according to the dosing regimen approved for psoriasis vulgaris.

86 ermatology with ustekinumab according to the dosing regimen approved for psoriasis.

87 by the kidneys or can affect renal function, dosing regimens are dramatically different in the neonat

88 These dosing regimens are especially challenging in the develo

89 ues, no difference was found between the two dosing regimens at any point over the study period for s

90 of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral ac

91 supports an alternative weekly (40 000 U/wk) dosing regimen, based on common clinical practice.

92 supports an alternative weekly (40,000 U/wk) dosing regimen, based on common clinical practice.

93 Using this individualised dosing regimen, both genders responded equally to GH rep

94 havior of each class of drug so that optimal dosing regimens can be designed.

95 tions about efficacy and safety of different dosing regimens can be made.

96 zation with CTB by any of several routes and dosing regimens can provide protection against live V. c

97 The basis for the selection of a steroid dosing regimen cannot be determined from registry data;

98 129 patients were treated at ten dosing regimens combining vemurafenib and cobimetinib: 6

99 Complex dosing regimens, costs, side effects, biodistribution li

100 The sCAR-T-cell dosing regimen could be tuned to provide efficacy compar

101 These findings suggest that dosing regimens could be individualised and tailored for

102 The improved selinexor dosing regimen described herein is crucial to help reduc

103 sistance emergence and incorporating them in dosing regimen design.

104 The two ibutilide dosing regimens did not differ in conversion efficacy (4

105 ic administration of CTLA4IgY100F in several dosing regimens did not protect from EAE, and in some pr

106 nclude proven activity, possible toxicities, dosing regimens, drug interactions, and costs.

107 effects or switch to the use of a once-daily dosing regimen due to compliance issues.

108 Studies to investigate the optimal dosing regimen, duration of clinical benefit, and effect

109 With the dosing regimens employed in the included studies, ESA th

110 axel and eribulin, we performed a 2-week MTD-dosing regimen, followed by a determination of drug phar

111 icacy of adalimumab double-blind maintenance dosing regimens following open-label induction for pedia

112 ) monotherapy using a consistent, comparable dosing regimen for 3 months after transplant.

113 The optimal induction dosing regimen for adalimumab in this study was 160 mg a

114 shes a rational and generally well tolerated dosing regimen for administration of tirofiban as adjunc

115 and the tumor microenvironment, the optimal dosing regimen for carrier-mediated agents, and the lack

116 The best route and dosing regimen for corticosteroid administration (oral v

117 provide critical information for optimizing dosing regimen for effectiveness and safety.

118 n this model of acute pancreatitis, the same dosing regimen for ethyl pyruvate also ameliorated bacte

119 ess efficacy, and to identify an appropriate dosing regimen for further development.

120 xic coordinates, we optimized the timing and dosing regimen for injection of mAb into the cortex.

121 Moreover, the use of a different dosing regimen for RTX and OBZ further complicates any i

122 ve allowed us to identify a linker, dose and dosing regimen for SN-38 conjugated to polyoxazoline-mod

123 As such, applying current (99m)Tc-sestamibi dosing regimens for 1- and 2-d protocols based on those

124 ndomized in a double-blind fashion to 1 of 5 dosing regimens for 12 weeks: placebo or 5, 20, 50, or 1

125 zumab or bevacizumab treatment and to 1 of 3 dosing regimens for 2 years.

126 nical trials will help determine the optimal dosing regimens for all of these agents, as well as the

127 linical trials demonstrate that the standard dosing regimens for each of these agents may be used to

128 ded to determine the most effective maternal dosing regimens for improving infant vitamin A status.

129 Effective dosing regimens for inadequately responding patients to

130 However, the optimal drug and dosing regimens for IPT remain to be determined.

131 tems ranging from coagulation to therapeutic dosing regimens for monoclonal antibodies.

132 methods for choosing drugs and for selecting dosing regimens for narrow-therapeutic-index drugs.

133 We determined optimal dosing regimens for neutrophil depletion and evaluated t

134 cific recommendations can be made on optimal dosing regimens for reversal; maintenance; and preventio

135 d in the development of increased and serial dosing regimens for somatic gene editing in vivo.

136 sponse or web-response system, to one of two dosing regimen groups (every 2 weeks, or every 2 weeks f

137 Hepatitis B immune globulin (HBIG) dosing regimens have been poorly defined, utilize numero

138 Moreover, appropriate dosing regimens have not been systematically evaluated t

139 Appropriate dose and dosing regimens, however, require further study.

140 ATION: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patie

141 Consistent with this mechanism, the repeat dosing regimen in a separate cohort of subjects led to i

142 The probabilities of each drug and dosing regimen in achieving pharmacodynamic targets were

143 with human IL-2 (Proleukin) in a therapeutic dosing regimen in chimpanzees, and found that although t

144 However, the optimal dosing regimen in settings in which human immunodeficien

145 es of the drug and to rationalize an optimal dosing regimen in the clinic, a method is needed to quan

146 ved with 480 mg vemurafenib, suggesting that dosing regimens in BRAF-driven cancers could warrant rea

147 armacodynamic effects of different prasugrel dosing regimens in patients on maintenance prasugrel the

148 ity of two long-term intermittent vismodegib dosing regimens in patients with multiple basal-cell car

149 dosing, ultimately supporting less frequent dosing regimens in preclinical tumor models compared wit

150 Patients received one of three dosing regimens in which aliquots of Surfaxin were admin

151 known Pgp substrate, using steady-state PAC dosing regimens in wild-type and Pgp knockout (mdr1a -/-

152 exposures owing to our current non-optimized dosing regimens initiate a chain of evolution driven eve

153 h the higher dosage suggest that the optimal dosing regimen is <50 mg/h.

154 However, the most beneficial dosing regimen is not known.

155 The ideal dosing regimen is unknown.

156 n can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avo

157 rats that had previously received a 4 d FEN-dosing regimen known to deplete forebrain 5-HT (D,L-FEN,

158 arrhythmias [n=4]) were randomized to 1 of 3 dosing regimens (low, medium, or high: load plus 47-hour

159 as species/strain, route of administration, dosing regimen, lowest effect level, and test outcome, w

160 A simplified dosing regimen may improve drug compliance in kidney tra

161 Extended TMZ dosing regimens may be superior by delivering the drug c

162 Higher dosing regimens maybe required in critically ill patient

163 hs were available (85%) and adherence to the dosing regimen (mean >80%) also were remarkably high.

164 ned by drug (ranibizumab or bevacizumab) and dosing regimen (monthly or as needed).

165 61), or placebo administered in an identical dosing regimen (n = 161), for a total of 18 months.

166 end points was observed with the therapeutic dosing regimen of BMS-345541, with use of the 100-mg/kg

167 The previously described interaction of dosing regimen of CAF with ErbB-2 was not dependent on p

168 cancer patients, further exploration of the dosing regimen of CDP860 is required to dissociate adver

169 ity was achieved in mice with a noncytotoxic dosing regimen of ethyl pyruvate shown previously to pro

170 The results show that a binge dosing regimen of METH to the rat increased plasma and b

171 important to more fully understand the best dosing regimen of MMF for induction versus maintenance t

172 f ranibizumab or bevacizumab and to a 2-year dosing regimen of monthly or pro re nata (PRN) or to mon

173 nversion to the same milligram-for-milligram dosing regimen of Neoral during period III (days 29-35).

174 apy regimens, leading to questions about the dosing regimen of prasugrel to administer if percutaneou

175 An individualized dosing regimen of ranibizumab 0.5 mg driven by stabiliza

176 the efficacy, long-term safety, and optimal dosing regimen of rituximab in this setting.

177 centration-dependent activity and once-daily dosing regimen of telavancin.

178 O(6)-BG when added to a 1-day dosing regimen of temozolomide was able to restore temoz

179 t dose of vehicle or TNP-470, a steady-state dosing regimen of TMZ was administered with subsequent c

180 The same dosing regimen of topical BRAF inhibitor does not increa

181 in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitori

182 bone who had previously received a standard dosing regimen of zoledronic acid and/or pamidronate dis

183 In animal studies, different dosing regimens of AdE2F-1(RC) administered to flank xen

184 tered MPTP with varying subcutaneous or oral dosing regimens of AEOL11207.

185 istance would be of great value in tailoring dosing regimens of antibiotics so as to maximize the dur

186 re randomized in a double-blind fashion to 3 dosing regimens of atopaxar (50, 100, or 200 mg daily) o

187 ients were randomly assigned to one of three dosing regimens of CAF.

188 antitative reporter to optimize sequence and dosing regimens of clinically relevant combination strat

189 dy determined the safety and efficacy of two dosing regimens of daclizumab compared with no antibody

190 we evaluated the efficacy and safety of five dosing regimens of denosumab in patients with breast can

191 ment interaction was observed between either dosing regimens of edoxaban and warfarin for the efficac

192 tion should be exercised on the extrapolated dosing regimens of ester drugs from other age groups.

193 Patients who received 1 of 6 dosing regimens of evolocumab in the parent studies and

194 ies enrolled 626 patients and used differing dosing regimens of fluconazole.

195 Various dosing regimens of HLA-derived peptides with and without

196 o determine the safety and efficacy of three dosing regimens of intracoronary urokinase for facilitat

197 Fixed-interval and variable dosing regimens of intravitreal bevacizumab improved vis

198 cokinetic and pharmacodynamic effects of two dosing regimens of IV followed by oral elinogrel (120 mg

199 tics (PK), efficacy, and safety of alternate dosing regimens of micafungin (MFG) for the treatment of

200 plant recipients should receive personalized dosing regimens of MMF, which would maximize efficacy an

201 ents were randomized to receive one of seven dosing regimens of sibrafiban, ranging from 5 mg daily t

202 drugs and other biological treatments, both dosing regimens of sirukumab were well tolerated and sig

203 We aimed to compare two dosing regimens of tosedostat.

204 med to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe

205 omized to receive one of three intracoronary dosing regimens of urokinase over 8 h (group A = 0.8 mil

206 were given either saline (control) or 1 of 2 dosing regimens of Vitaxin (high dose, 5.0 mg/kg, and lo

207 ent once-daily, prolonged-release tacrolimus dosing regimens on renal function after de novo liver tr

208 ons may be managed by modifying the levodopa dosing regimen or by adding several other medications, s

209 Further studies with different dosing regimens or second agents seem warranted.

210 ith regards to specific indications, optimal dosing regimens, or treatment efficacy.

211 n study design, participants, drugs used and dosing regimens, outcome measures, side-effects, and sou

212 ranibizumab or bevacizumab with 3 different dosing regimens over a 2-year period.

213 anibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period.

214 did not differ by treatment group, drug, or dosing regimen (P > .01 for all).

215 The 2 riboflavin dosing regimens produced equivalent reduction in the max

216 All three alternative dosing regimens produced HI, RBC transfusion independenc

217 mab administered as per a VA-guided flexible dosing regimen recommended in the European ranibizumab S

218 ability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abaca

219 plasma concentrations of fomepizole with the dosing regimen, residual illness or disability, and deat

220 rphine following intermittent and continuous dosing regimens, respectively.

221 Furthermore, weight-based dosing regimens resulted in lower overall doses in femal

222 erapy, as well as indications for their use, dosing regimens, safety, and efficacy.

223 These customized dosing regimens should also be given as soon as practica

224 nce the effect waned over time, intermittent dosing regimens should be considered for long-term eradi

225 Both benralizumab dosing regimens significantly improved prebronchodilator

226 The two benralizumab dosing regimens significantly reduced the median final o

227 per day Brd4 inhibitor JQ1 in a therapeutic dosing regimen substantially attenuated lung fibrosis in

228 sine administration at clinically meaningful dosing regimens suppressed P. aeruginosa pathogenicity i

229 Protection was more profound with an acute dosing regimen than with daily MPTP administration over

230 This review focuses on a novel dosing regimen that has achieved significant clinical ac

231 with the FDA-approved drug ritonavir using a dosing regimen that resulted in plasma concentrations wi

232 lling 8-15 patients), and used agents and/or dosing regimens that are now less commonly used in clini

233 treatment, along with the study of modified dosing regimens that provide higher exposure, is warrant

234 ical models can be used to identify rational dosing regimens that suppress the amplification of the r

235 Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lowe

236 atients treated overall with the recommended dosing regimen, the median number of prior systemic ther

237 Across all dosing regimens, the most common adverse events were dia

238 This permitted comparison of rituximab dosing regimens, the value of continuing immunosuppressi

239 able optimized dosing, the use of customized dosing regimens through either evidence-based dosing nom

240 ect may have been obscured by differences in dosing regimens, time off the filter, or altered pharmac

241 tion of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we

242 n was obtained regarding patient population, dosing regimen, type of therapeutic goals or end points

243 or racial origin, body-mass index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-s

244 00 mg tedizolid phosphate per day in humans (dosing regimen used in phase 2 and 3 clinical trials).

245 The dosing regimen used in renal transplant recipients is mo

246 The dosing regimen used in the present study is considerably

247 With the dosing regimen used in this study, alteplase produces gr

248 ted the hypothesis that the patient-specific dosing regimen used with (131)I-tositumomab results in l

249 e marrow toxicity than does the weight-based dosing regimen used with (90)Y-ibritumomab tiuxetan.

250 case studies that investigated the different dosing regimens used for the 3 intravitreal anti-vascula

251 There is great variation in the drug dosing regimens used for thrombolysis and in the inciden

252 Simulation of a variety of ceftazidime dosing regimens using the mean pharmacokinetic parameter

253 efficacy of 5 SAR236553/REGN727 (SAR236553) dosing regimens versus placebo at week 12 in patients wi

254 odynamic target attainment for antimicrobial dosing regimens vs. observed MIC distributions.

255 okinetic parameters with a convenient single-dosing regimen warrant further disease-directed evaluati

256 Adherence to the dosing regimen was 91.8% among subjects who completed th

257 inistration CYP activity; the St John's wort dosing regimen was continued for 48 hours.

258 Large variability in the micafungin dosing regimen was observed; 78 (75%) patients received

259 ies of toxicity studies of ligands 1- 3, the dosing regimen was shown to have a profound effect in an

260 An effective dosing regimen was then selected for testing in swine.

261 valence for the treatment difference between dosing regimens was considered clinically relevant.

262 clinical allotransplantation, but using the dosing regimens we used, is not a tolerizing therapy in

263 Using a q4dx4 dosing regimen, we also found that POx/SB-T-1214 signifi

264 Intermittent and continuous dosing regimens were analysed.

265 The effects of these two dosing regimens were compared with our previous findings

266 Four PV701 intravenous dosing regimens were evaluated: (1) single dose: one dos

267 ill patients treated with epoetin alfa, all dosing regimens were well tolerated and appeared to effe

268 elf-administering cocaine underwent a 6-week dosing regimen with fluoxetine designed to approximate s

269 Since then, various modified dosing regimens with the aim of lessening the treatment

270 Since then, various modified dosing regimens with the aim of lessening the treatment

271 aparin administration demonstrated that both dosing regimens would reach target 3-hour plasma concent